Key result
125I-iodovinyltetrabenazine specifically binds to VMAT sites and labels VMAT-rich regions in rat brains.
125I-iodovinyltetrabenazine demonstrates high specific binding to VMAT sites, suggesting its potential utility as an in vitro marker for neuronal loss in neurodegenerative diseases.
Binding characteristics of a novel radioiodinated tetrabenazine (TBZ) analog (iodovinyltetrabenazine; 125I-TBZ-Fraction I) were evaluated. In rat striatal homogenates, 125I-TBZ-I displayed a pharmacological profile consistent with specific binding to vesicular monoamine transport (VMAT) sites. In vitro autoradiographic studies using rat brain sections further demonstrated that 125I-TBZ-I labeled the regions rich in VMAT sites, and it may be a useful marker for these sites. This novel radioiodinated ligand, with high specific activity and high binding affinity, may provide a powerful tool for the in vitro assessment of neuronal loss in various neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Kung et al. (1994) studied this question. 125I-iodovinyltetrabenazine (125I-TBZ-Fraction I) was evaluated on Binding characteristics to vesicular monoamine transport (VMAT) sites. 125I-iodovinyltetrabenazine displayed specific binding to vesicular monoamine transport sites in rat striatal homogenates and labeled VMAT-rich regions in rat brain sections.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: